

Liaison Division, provides various personnel management services to a number of diverse Presidential commissions, committees, boards and other agencies through reimbursable administrative support agreements. This notice is proceeded on behalf of the client agencies, and it supersedes all other notices in the **Federal Register** on this subject.

Because of their small size, a Performance Review Board register has been established in which SES members from the client agencies participate. The Board is composed of SES members from various agencies. From this register of names, the head of each client agency will appoint executives to a specific board to serve a particular client agency.

The members whose names appear on the Performance Review Board standing roster to sere client agencies are:

Administrative Conference of the U.S.

Gary J. Edles, General Counsel
Jeffrey S. Lubbers, Research Director

Barry M. Goldwater Scholarship and Excellence in Education Foundation

Gerald J. Smith, Executive Secretary

Board of International Broadcasting

Richard McBride, Executive Director
John A. Lindburg, General Counsel
Patricia H. Schlueter, Director of Financial and Congressional Affairs
Bria T. Conniff, Inspector General

Committee for Purchase From People Who Are Blind or Severely Disabled

Beverly L. Milkman, Executive Director

Defense Nuclear Facilities Safety Board

Kenneth M. Pusateri, General Manager
Joseph R. Neubeiser, Deputy General Manager
Robert M. Anderson, General Counsel
Richard A. Azzaro, Deputy General Counsel for Policy and Litigation
George W. Cunningham, General Engineer
Joyce P. Davis, Chief, Health Physics Branch
Wallace R. Kornack, Assistant Director for Engineering
Steven L. Krahn, Assistant Director for Weapon Programs
Lester A. Ettliger, Assistant Director for Standards

Harry S Truman Scholarship Foundation

Louis H. Blair, Executive Secretary

Japan-United States Friendship Commission

Eric J. Gangloff, Executive Director

Office of Navajo and Hopi Indian Relocation

Christopher J. Bavasi, Executive Director
Michael J. McAlister, Deputy Executive Director

Artic Research Commission

Garrett W. Brass, Executive Director

National Mediation Board

Ronald M. Ethers, General Counsel

Dated: July 18, 1995.

Calvin R. Snowden,

Director.

[FR Doc. 95-18486 Filed 7-26-95; 8:45 am]

BILLING CODE 6820-34-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

CDC Recommendations for Civilian Communities Near Chemical Weapons Depots: Guidelines for Medical Preparedness; Correction

A notice was published in the **Federal Register** on June 27, 1995 (60 FR 33308), entitled, "CDC Recommendations for Civilian Communities Near Chemical Weapons Depots: Guidelines for Medical Preparedness." This notice is corrected as follows:

On page 33309, first column, line 6 of the second paragraph, change "falls" to "fall"; and in the second column, line 9, under the heading: 1. Personal Protective Equipment (PPE), change "have" to "has" and in line 11, change "portable" to "powered." On page 33311, second column, line 8, under the heading: 5. Personal Protective Equipment (PPE), change "have" to "has."

Dated: July 21, 1995.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-18433 Filed 7-26-95; 8:45 am]

BILLING CODE 4163-18-P

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meeting and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee

hotline, which will disseminate current information and information updates, can be accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETING: The following advisory committee meeting is announced:

Subcommittee Meeting of the National Task Force on AIDS Drug Development on Drug Development Issues

Date, time, and place. September 13 and 14, 1995, 8:30 a.m., Gaithersburg Hilton Hotel, Grand Ballroom, 629 Perry Pkwy., Gaithersburg, MD. A limited number of overnight accommodations have been reserved at the Gaithersburg Hilton Hotel. Attendees requiring overnight accommodations may contact the hotel at 301-977-8900 and reference the task force. Interested persons are encouraged to register early because space is limited.

Type of meeting and contact person. Open subcommittee discussion, September 13, 1995, 8:30 a.m. to 11:45 a.m.; open public hearing, 11:45 a.m. to 12:15 p.m., unless public participation does not last that long; open subcommittee discussion, 12:15 p.m. to 4:45 p.m.; open subcommittee discussion, September 14, 1995, 8:30 a.m. to 11:45 a.m.; open public hearing, 11:45 a.m. to 12:15 p.m., unless public participation does not last that long; Nancy L. Stanisic, Office of AIDS and Special Health Issues (HF-12), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-0104, or FDA Advisory Committee Information Hotline, 1-800-741-8138 (301-443-0572 in the Washington, DC area), National Task Force on AIDS Drug Development, code 12602.

General functions of the task force. The task force shall identify any barriers and provide creative options for the rapid development and evaluation of treatments for human immunodeficiency virus (HIV) infection and its sequelae. It also advises on issues related to such barriers, and provides options for the elimination of these barriers.

Open subcommittee discussion. The subcommittee will review, discuss, and clarify issues concerning the